These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22844684)

  • 1. Silodosin: erectile and ejaculatory disorders.
    Prescrire Int; 2012 May; 21(127):129. PubMed ID: 22844684
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
    Yokoyama T; Hara R; Fukumoto K; Fujii T; Jo Y; Miyaji Y; Nagai A; Sone A
    Int J Urol; 2011 Mar; 18(3):225-30. PubMed ID: 21272091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silodosin causes impaired ejaculation and enlargement of seminal vesicles in sexually active men treated for lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Bozkurt O; Demir O; Sen V; Esen A
    Urology; 2015 May; 85(5):1085-1089. PubMed ID: 25744372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of silodosin on sexual function - realistic picture from the everyday clinical practice.
    Capogrosso P; Serino A; Ventimiglia E; Boeri L; Dehò F; Damiano R; Briganti A; Montorsi F; Salonia A
    Andrology; 2015 Nov; 3(6):1076-81. PubMed ID: 26446512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silodosin.
    Prescrire Int; 2011; 20(118):180. PubMed ID: 21751751
    [No Abstract]   [Full Text] [Related]  

  • 6. Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial.
    Yamaguchi K; Aoki Y; Yoshikawa T; Hachiya T; Saito T; Takahashi S
    Int J Urol; 2013 Dec; 20(12):1234-8. PubMed ID: 23731168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.
    Osman NI; Chapple CR; Cruz F; Desgrandchamps F; Llorente C; Montorsi F
    Expert Opin Pharmacother; 2012 Oct; 13(14):2085-96. PubMed ID: 22924980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the use of silodosin to treat benign prostatic hyperplasia really offer something new?
    Morgia G
    Eur Urol; 2011 Mar; 59(3):353-5; discussion 355. PubMed ID: 21130562
    [No Abstract]   [Full Text] [Related]  

  • 9. Silodosin for benign prostatic hyperplasia.
    Cantrell MA; Bream-Rouwenhorst HR; Hemerson P; Magera JS
    Ann Pharmacother; 2010 Feb; 44(2):302-10. PubMed ID: 20071497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silodosin and its potential for treating premature ejaculation: a preliminary report.
    Sato Y; Tanda H; Nakajima H; Nitta T; Akagashi K; Hanzawa T; Tobe M; Haga K; Uchida K; Honma I
    Int J Urol; 2012 Mar; 19(3):268-72. PubMed ID: 22188258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silodosin (Rapaflo) for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2009 Jan; 51(1303):3-4. PubMed ID: 19122568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Profile of silodosin].
    Montorsi F
    Urologiia; 2013; (2):112-4, 116-7. PubMed ID: 23789376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia.
    Homma Y; Kawabe K; Takeda M; Yoshida M
    Urology; 2010 Dec; 76(6):1446-50. PubMed ID: 20472263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.
    Yoshida M; Kudoh J; Homma Y; Kawabe K
    Int J Urol; 2012 Apr; 19(4):306-16. PubMed ID: 22251148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experience of the use of silodosin in acute urinary retention caused by benign prostatic hyperplasia].
    Neĭmark AI; Nozdrachev NA
    Urologiia; 2013; (4):47-8, 50-1. PubMed ID: 24159765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.
    Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G
    J Urol; 2013 Jan; 189(1 Suppl):S122-8. PubMed ID: 23234617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.
    Schilit S; Benzeroual KE
    Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
    BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.
    Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G
    J Urol; 2009 Jun; 181(6):2634-40. PubMed ID: 19371887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.